Xoft Inc

Website Links

Description

UltraMed Technology Corporation’s management team has more than 160 years experience in the medical industry, and keeps very good relationships with key opinion leaders in these fields, especially in the treatment of cancer. The Xoft Axxent System has been approved by Taiwan FDA for use anywhere in the body, including early-stage breast cancer, gynecological cancers and non-melanoma skin cancer. Currently the Xoft Axxent System is the leading product for the treatment of early-stage breast cancer with IORT in Taiwan and has entered into a growth stage.

Xoft Technical Support Service is dedicated to providing the best support for our products whenever and wherever needed. From site planning to service support agreements, on-site support and technical phone support, Xoft is ready to help.

For over 100 years, radiation therapy has been widely used to help reduce the recurrence of cancer and improve survival, and more than 1 million cancer patients in the U.S. receive radiation every year.

Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

Products & services

Similar companies nearby